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In adult mammals, cardiomyocytes are known to reactivate an embryonic gene-expression program after
injury. In this issue ofCell StemCell, Kubin et al. (2011) show that oncostatinM regulates this dedifferentiation
which, while beneficial for recovery from acute injury, if persistent results in heart failure in both rodents and
humans.Heart disease is the leading cause of
death in the Western world; therefore,
understanding how the adult heart re-
sponds to common injuries, such as
myocardial infarction (MI) or dilated
cardiomyopathy (DCM), is a crucially im-
portant research question. The mamma-
lian heart has a very limited range of
responses to injury and stress, but most
insults ultimately lead to cardiomyocyte
hypertrophy (an increase in cell size but
not cell division) or cardiomyocyte drop-
out induced by apoptosis. Although the
mammalian heart cannot robustly regen-
erate after cardiomyocyte proliferation
ceases, postnatal cardiomyocytes do
dedifferentiate after injury and re-express
markers of embryonic cardiomyocytes
similar to what occurs in zebrafish hearts,
which regenerate efficiently after injury.
The underlying mechanism regulating
this dedifferentiation, and its role in the
response to cardiac injury, is largely un-
known. In the current issue of Cell Stem
Cell, Kubin et al. (2011) characterize the
signaling pathways leading tomammalian
cardiomyocyte dedifferentiation after in-
jury. They show that the inflammatory
cytokine oncostatin M (OSM) is induced
at high levels in human patients with
DCM and that exposure of rodent cardio-
myocytes to OSM increases Erk1/2 sig-
naling, which leads to a variety of re-
sponses including re-expression of
embryonic heart markers such as smooth
muscle a-actin. Interestingly, Kubin et al.
(2011) also observed increased or ectopic
expression in OSM-treated adult cardio-
myocytes of several stem cell genes
including Runx1, c-kit, and Dab2. Using
a chronic mouse model of increasedcardiac macrophage infiltration, which
recapitulates major features of human
DCM, the authors also show improved
cardiac function after genetic loss of
OCM signaling. When using a model of
acute ischemic injury, however, the
authors found that genetic loss of OCM
signaling resulted in a worsening of
cardiac function leading to increased
lethality. Together, these data suggest
that OCM confers a protective signal
during the early stages of cardiac injury
and repair by promoting cardiomyocyte
dedifferentiation, potentially by activating
a stem cell gene-expression signature.
However, persistent OCM signaling,
such as might occur in chronic heart con-
ditions, prevents cardiomyocytes from
redifferentiating, which is important to
maintain contractile force and function.
One of the more interesting findings
from Kubin et al. (2011) is the increased
expression of stem cell markers Runx1,
c-kit, and Dab2 in OCM-treated cardio-
myocytes. A previous report showed
that Runx1 was upregulated in human
and rat myocardium after ischemic injury,
which may account for the increase
observed after OCM treatment (Gatten-
lo¨hner et al., 2003). Dab2 is a target of
GATA transcription factors and its OCM-
induced increase may reflect increased
expression or activity of GATA4/6, which
has been reported during cardiac hyper-
trophy (Molkentin et al., 1998; Morrisey
et al., 2000; van Berlo et al., 2010). c-kit
has been used as a surrogate cardiac
stem/progenitor marker, and there is
much interest in identifying cardiac stem
cells in the postnatal heart in the hopes
of improving cardiac repair after injuryCell Stem Cell 9,(Beltrami et al., 2003). However, whether
a postnatal cardiac progenitor exists that
is capable of generating newmyocardium
after injury remains unclear. Kubin et al.
(2011) show that c-kit is upregulated in
response to OCM treatment, which could
be interpreted as increased activation of
a postnatal cardiac stem cell population.
The implication from some previous
studies on c-kit-positive cells in the adult
myocardium is that they act as resident
cardiac stem cells that robustly respond
to injury and generate new tissue.
However, if this is true, it is hard to recon-
cile these findings with the almost
complete inability of the adult mammalian
heart to regenerate after injury. With the
current paper in mind, previous findings
of a c-kit-positive population of cardio-
myocytes acting as a stem cell population
could be reinterpreted. c-kit-positive cells
may normally exist at low levels in the
postnatal heart, but, rather than defining
a stem cell population, they may repre-
sent dedifferentiated cardiomyocytes.
What these dedifferentiated cardiomyo-
cytes are doing in the postnatal heart is
unclear, but they may be present at
a stochastic level and increase in
response to injury or stress, which could
make them appear to act as cardiac
stem cells in the adult heart.
Because the mammalian heart has
such a limited ability to respond to injury
and lacks overt regenerative capacity,
one of the ‘‘holy grails’’ of current cardiac
stem cell research is amethod to promote
cardiomyocyte proliferation in the setting
of acute or chronic injury. The current
report by Kubin et al. shows that OCM
signaling does promote a pro-proliferativeNovember 4, 2011 ª2011 Elsevier Inc. 387
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Previewsresponse due, at least in part, to
increased Erk1/2 signaling. Previous
reports have shown that Fgf signaling
promotes proliferation of embryonic car-
diomyocytes and Erk1/2 acts down-
streamof Fgf signaling in this process (En-
gel et al., 2006). Kubin et al. (2011) show
that combined treatment of cardiomyo-
cytes with Fgf2 and OCM increased entry
into S-phase more efficiently than treat-
ment with individual factors. Thus, in
response to OCM treatment, cardiomyo-
cytes do dedifferentiate and try to prolif-
erate. As yet unknown blocks to cell cycle
re-entry are still present, however, pre-
venting a robust proliferative response to
OCM.
Pathways that regulate the dedifferenti-
ated state of cardiomyocytes are clearly
important and may eventually lead to
methods to promote cardiomyocyte re-
placement after injury in the human heart.
The major roadblock to such an approach
still appears to be the inability of cardio-
myocytes to fully re-enter the cell cycle.
Although increased cardiomyocyte cell
division after treatment with neuregulin or388 Cell Stem Cell 9, November 4, 2011 ª20ErbB4 has been reported, the overall effect
is still rather low (i.e., approximately 0.6%
of cardiomyocytes in vivo responded to
these treatments) (Bersell et al., 2009).
Cardiomyocytes need to maintain proper
contractile function or the biomechanics
of the heart will fail. Although lower verte-
brate cardiomyocytes do go through a
process of dedifferentiation, proliferation,
and redifferentiation to repair injury, the
high cardiac output in mammalian hearts
may preclude such a mechanism as it
could lead to a lethal drop in cardiac out-
put because of decreased contractility.
The finding that OCM promotes dedif-
ferentiation, however, may help lead to
approaches that could promote dediffer-
entiation and ultimately increase cardio-
myocyte replacement after injury-induced
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How DNA methyltransferases, with their limited target specificity, establish cell-type-specific epigenetic
patterns is poorly understood. Schu¨beler and colleagues (Lienert et al., 2011) now show that methylation-
determining regions (MDRs) within promoter regions are sufficient to recapitulate endogenous patterns
and dynamics of DNA methylation.DNA methylation of CpG dinucleotides is
required for normal mammalian develop-
ment. Most of the genome contains few
CpGs and they tend to be methylated
across all cell types. Unmethylated
CpGs are typically found in clusters called
CpG islands (CGIs), which comprise
about 1%–2% of the genome. About half
of CGIs in mouse and human are associ-
ated with transcription start sites (Deatonand Bird, 2011), and many are linked to
housekeeping genes and developmental
regulators. While the enzymes respon-
sible for establishing and maintaining
DNA methylation have been well-studied
and genome-scale data sets continue
to shed light on its genomic distribution
(Meissner, 2010), it remains less clear
how particular sites in the genome are
protected and others are targeted formaintenance or de novo methylation.
None of the three catalytically active DNA
methyltransferases (Dnmt1, 3a, and 3b)
shows a particular target preference that
could explain cell-type-specific methyla-
tion patterns, suggesting that alternative
mechanisms must be in place to either
direct or inhibit their recruitment.
In a recent issue of Nature Genetics,
Schu¨beler andcolleaguessetout to further
